MedPath

Response to increased versus standard dose of oral Vitamin D in obese and overweight children 5 to 12 years of age.

Phase 1
Conditions
Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases
Registration Number
CTRI/2023/07/055191
Lead Sponsor
none
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

overweight / obese children of age 5-12 years presenting to the pediatric OPDof cnbc delhi will be screened and included in the study if their serum 25(OH) vitamin D levelks are less than 20ng/ml

Exclusion Criteria

1) children with confirmed or suspected malabsorption, renal or hepatic disorders.

2) children who had received vitamin D in therapeutic doses in the last 6 months.

3) children who had received drugs that may interferev with vitamin D metabolism like anticonvulsants, steriods, chemotherapy, antitubercular, h2 blockers, and thiazide diuretics and those on any herbal or ayurvedic medicines.

4) children with any known systemic illness oer metabolic disroders known to be assiociated with obesity wither before or during study or subjects with sypmtosm s/o hypothalamic obesity like hypothyroidism, cushing syndrome etc.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to evaluate the rise in levels of serum 25(OH)D levels in each group from baseline to 30 days after the last dose of vitamin D.Timepoint: From baseline to 30 days post supplementation of oral Vitamin D .
Secondary Outcome Measures
NameTimeMethod
secondary outcome: <br/ ><br>1) to measure serum 25(OH)d levels at day 7 <br/ ><br>2)serum calcium levels post suplementation day 7 & 30 <br/ ><br>3) urinary calcium creatinine ratio levels post supplementation day 7 and day 30.Timepoint: day 7 & day 30 post supplmentation
© Copyright 2025. All Rights Reserved by MedPath